Robert N. Husson, MD (contact Robert Husson)
About Robert Husson
Sladjana Prisic, PhD (contact Sladjana Prisic)
Sladjana received B.Sc. in Biochemistry from the the Faculty of Chemistry, University of Belgrade. She moved to Iowa State to work on plant enzymes in Dr. Reuben Peters group where she obtained her Ph.D. degree in Biochemistry. While working on plant terpene cyclases, Sladjana briefly studied similar enzymes from Mycobacterium tuberculosis and instantly ‘fell in love’ with this dangerous pathogen. In pursuit to save the world from tuberculosis, she switched fields and joined Dr. Husson lab in 2007 to learn mycobacteriology. The end of TB is near!
Currently her interests are eukaryotic like Ser/Thr kinases from Mtb and their substrates. Initially Sladjana and collaborators identified over 500 phosphorylation sites on 300 Mtb proteins in the largest phosphoproteomic study published for any prokaryote. She uses this list of Mtb phosphoproteins to study in more detail roles of these modifications in pathogenesis and to identify new drug targets.
Sladjana recently received CFAR (Center for AIDS Research) Award to study how/if phosphorylation of certain ribosomal proteins regulate protein translation and to find out if this regulation have a role in Mtb persistence.
Jared Sharp, PhD (contact Jared Sharp)
Dr. Jared Sharp completed his BS at the University of Delaware and his PhD at the Rutgers University/University of Medicine and Dentistry of New Jersey. He is currently using a human in vitro granuloma model for M. tuberculosis infection to identify M. tuberculosis genes critical for the survival of the bacteria within the granuloma and human genes that play a role in restricting bacterial growth within the granuloma.
Xavier Carette, PhD (contact Xavier Carette)
Xavier received his B. Sc. in Genetics & Microbiology and B. Sc. in Biochemistry from the University of Sciences and Technologies of Lille in France. He obtained his PhD degree from the University of Law and Health at Lille, France. During his PhD, he studied the improvement of ethionamide, a second line antituberculous treatment. TB is a very peculiar disease which is not easily diagnosed nor treated. In some cases, with the development of drug resistance strains, we have to use second line compounds which are less effective than first line and bear much more severe side effects. Those effects are dose related so it was proposed to decrease the dose of ethionamide without losing its activity. This is possible because ethionamide is a compound that needs to be activated by the mycobacteria. His research in the molecular pathways in which this activation occurred permitted the development of compromising compounds in collaboration with several leading teams in drug development.
Interested by the molecular mechanisms of metabolism pathways, he decided to pursue his research in the laboratory of Dr Robert Husson as a post doctoral trainee. His research focuses on the study of two Ser/Thr kinases: PknA and PknB. These two essential kinases are highly implicated in regulating cell wall synthesis, cell division, cell envelope lipid synthesis, stress responses and central carbon metabolism. Currently, his goal is to decipher the implication of these two kinases in these pathways using lipidomics, metabolomics, transcriptomics and proteomics in collaboration with leading teams in each platform.